Clinical trials: Normal Skin
Invasive Breast Cancer, Ductal Carcinoma in Situ
Preoperative Testing of the Anti-Progesterone Mifepristone in Early Stage Breast Cancer
The primary objective of this study is to identify the group of women with early stage breast cancer most likely to benefit from treatment with the selective progesterone receptor modulator (SPRM) mifepristone.
- Trial name
- NCT01138553
- Testing
- Mifepristone
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of California, San Diego
Cytomegalovirus Infections
Immune Response to Cytomegalovirus
This study will evaluate immune responses against cytomegalovirus (CMV). About 80 percent of adults have been exposed to this virus. CMV typically remains dormant (inactive) in the body, causing no problems.
- Trial name
- NCT00034437
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Post-Surgical Complication, Breast Cancer Surgery
The Efficacy of Using Pentoxifylline in Patients Undergoing Breast Cancer Surgery
The goal of this clinical trial is to assess the efficacy of pentoxifylline in reducing postsurgical complications for breast cancer patients undergoing breast cancer surgery.
- Trial name
- NCT06087237
- Testing
- Pentoxifylline, paracetamol +ketorolac
- Where
- Egypt
- Volunteers
- 92 people
- Sponsor
- Mansoura University
Epidermolysis Bullosa
Study of Cellutome System for Treatment of Individual Lesions in EB Pts
Few but persistent wounds often remain even after successful hematopoietic cell transplantation for systemic genodermatosis epidermolysis bullosa (EB).
- Trial name
- NCT02670837
- Testing
- Cellutome Epidermal Harvesting System
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Antineutrophil Cytoplasmic Antibody-associated Vasculitis
CC-97540 in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis
The purpose of this study is to evaluate the safety of CC-97540 in relapsed or refractory severe antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.
- Trial name
- NCT07388277
- Testing
- CC-97540, Lymphodepletion Chemotherapy
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Marcela V. Maus, M.D.,Ph.D.
Arthritis, Psoriatic
Study to Evaluate the Real-World Effectiveness, Safety and Tolerability of Treatment With Apremilast in Psoriatic Arthritis Patients Followed in Canadian Routine Care (APPRAISE)
This will be a Canadian observational study utilizing a prospective cohort design. Patients with active psoriatic arthritis (PsA) for whom the treating physician has decided, prior to and independently of enrollment in the study…
- Trial name
- APPRAISE (NCT03608657)
- Testing
- Apremilast
- Where
- 19 sites in Canada
- Volunteers
- 102 people
- Sponsor
- Amgen
Pemphigus Vulgaris
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
A phase 1/2, open-label, safety and dosing study of autologous CART cells (desmoglein 3 chimeric autoantibody receptor T cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T cells [CABA-201]) in subjects with active…
- Trial name
- NCT04422912
- Testing
- DSG3-CAART, CABA-201
- Where
- 13 sites in United States
- Volunteers
- 40 people
- Sponsor
- Cabaletta Bio
Melanoma, Acral Melanoma
Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma
Neoadjuvant therapy is feasible in stage Ⅱ-Ⅲ melanoma, Carrelizumab combined with apatinib and temozolomide has synergistic antitumor effects and may improve pathological response.
- Conditions
- Melanoma, Acral Melanoma, Temozolomide, Apatinib
- Trial name
- NCT05512481
- Testing
- Camrelizumab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University Cancer Hospital & Institute
Recessive Dystrophic Epidermolysis Bullosa
A Study of PTR-01 in Recessive Dystrophic Epidermolysis Bullosa
Protocol PTR-01-002 is a 3-part Phase 2, open-label study of PTR-01. While new patients will be enrolled, priority will be given to patients that satisfactorily completed study PTR-01-001.
- Trial name
- NCT04599881
- Testing
- PTR-01
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Phoenix Tissue Repair, Inc.
Dermatitis, Nevus
Assessment of Digital Imaging as a Tool for Diagnosing Psoriasis, Hand Rashes and Unusual Moles
This study will evaluate whether digital photography is a reliable tool for diagnosing hand rashes, psoriasis and unusual moles.
- Conditions
- Dermatitis, Nevus, Psoriasis
- Trial name
- NCT00005781
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- National Cancer Institute (NCI)
Healthy
TopQ Cut-off Determination Study For 3D-OCT 1 Maestro and 3D OCT-2000
To determine optimal cut-off value for the TopQ cut-off on the Maestro and 3D OCT-2000.
- Trial name
- NCT02203981
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Topcon Medical Systems, Inc.
Urothelial Carcinoma, Melanoma
SAbR Induced Innate Immunity in Urothelial Carcinoma, Melanoma, and Cervical Carcinoma
The study is an exploratory prospective, single center study with correlative endpoints. The study will investigate the association of tumor cGAS STING signaling with SAbR.
- Conditions
- Urothelial Carcinoma, Melanoma, Cervical Carcinoma in Situ
- Trial name
- NCT02986867
- Testing
- SAbR Treatment of Lesions
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Texas Southwestern Medical Center
Locally Advanced or Metastatic Solid Tumours
A Study to Evaluate Safety and Efficacy of Multiple Dosing With VB10.NEO and Bempegaldesleukin (NKTR-214) Immunotherapy in Patients With Locally Advanced or Metastatic Cancer
This open labelled first in human dose phase 1/2a study is designed to evaluate safety, feasibility and efficacy of multiple dosing with individualised VB10.NEO and bempegaldesleukin (NKTR-214) immunotherapy in patients with…
- Trial name
- DIRECT-01 (NCT03548467)
- Testing
- VB10.NEO, Bempegaldesleukin
- Where
- 6 sites in Germany
- Volunteers
- 41 people
- Sponsor
- Nykode Therapeutics ASA
Breast Cancer
Computed Optical Margin Assessment for Breast Cancer Surgery, Phase I (Part A)
This multi-center, prospective, open label study analyzed specimens from fifty subjects at two study sites. Patients scheduled to undergo breast-conserving surgery were recruited in accordance with the inclusion and exclusion…
- Trial name
- NCT01699867
- Testing
- Optical coherence tomography
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Diagnostic Photonics, Inc.
Wound of Skin
DermaClose DUKE Fasciotomy and Wound Study
To evaluate the clinical performance of DermaClose and DermaClose XL Continuous External Tissue Expander (CETE) devices to reduce wound size and/or assist with closure in acute full thickness wounds of the skin and assess the…
- Trial name
- NCT05330767
- Testing
- DermaClose Continuous External Tissue Expander Device, DermaClose XL Continuous External Tissue Expander Device, Conventional wound dressings
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Baxter Healthcare Corporation
Rheumatoid Arthritis (RA)
A Study to Assess Safety and Efficacy of ASP015K in Participants With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to Methotrexate (MTX)
The purpose of this study is to verify the superiority of ASP015K in combination with MTX or with other disease-modifying antirheumatic drugs (DMARDs) over placebo in terms of efficacy in participants with rheumatoid arthritis…
- Trial name
- NCT03660059
- Testing
- Peficitinib, Plaebo, Disease-modifying antirheumatic drugs (DMARDs)
- Where
- 43 sites in China, South Korea and 1 more
- Volunteers
- 385 people
- Sponsor
- Astellas Pharma China, Inc.
Rheumatoid Arthritis
Effects of Acute Exercise on BDNF Levels in Rheumatoid Arthritis Patients
Background: RA may progress with articular and non-articular involvement.Depression prevelance is found to increase for RA patients according to healthy population and to be correlated with pain, decreased quality of life…
- Trial name
- NCT04254146
- Testing
- Aerobic exercise
- Where
- 4 sites in Turkey (Türkiye)
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Gazi University
Diaper Dermatitis
Neonatal Intensive Care Unit (NICU) Diaper Dermatitis: Prevention and Treatment With Airtime
The purpose of this study is to investigate the use of 3-5 minutes air therapy for the prevention and treatment of diaper dermatitis in infants 30 weeks and older receiving care in the neonatal intensive care unit (NICU).
- Trial name
- NCT06958003
- Testing
- Air Therapy
- Where
- United States
- Volunteers
- 320 people
- Sponsor
- TriHealth Inc.
Actinic Keratoses
Therapeutic Equivalence of Fluorouracil Cream, 5% Compared With Fluorouracil 5% Topical Cream of MylanPharmaceuticals Inc., U.S.A in the Treatment of Actinic Keratosis
Fluorouracil is recommended for the topical treatment of multiple actinic or solar keratoses. In the 5% strength, it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical…
- Trial name
- NCT05078827
- Testing
- Test Product (A): Fluorouracil Cream, 5% topical cream, Reference Product (B): Fluorouracil 5% Topical Cream of Mylan Pharmaceuticals Inc., Morgantown, WV 26505 U.S.A.
- Where
- 7 sites in United States
- Volunteers
- 458 people
- Sponsor
- Encube Ethicals Pvt. Ltd.
Venous Leg Ulcer, Chronic Wounds
Evaluation of the Efficacy of Hyalomatrix® in the Healing of Chronic Venous Leg Ulcers
This is a randomized controlled trial evaluating the efficacy of HYALOMATRIX in conjunction with standard of care vs. standard of care alone in treating venous leg ulcers.
- Trial name
- NCT07335861
- Testing
- Hyalomatrix, Standard of Care
- Where
- 4 sites in United States
- Volunteers
- 122 people
- Sponsor
- NuScience Medical Biologics, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.